13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • Enza-P

    Acronym: 

    Enza-P

    ACTRN/NCT /ethics: 

    Scientific title: 

    A randomised phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castrate-resistant prostate cancer treated with enzalutamide (ANZUP 1901)

    Summary of trial and patient characteristics

    Cancer Type Prostate
    Trial Type Early detection, diagnosis, prognosis, Treatment
    Phase Tumour Stream Prostate
    Age Range 18 years and older Cancer Stage Metastatic or Widespread
    Sex Male Anticipated Start Date
    Molecular Target Anticipated End Date
    Cancer Type Prostate
    Trial Type Early detection, diagnosis, prognosis, Treatment
    Phase
    Age Range 18 years and older
    Sex Male
    Molecular Target
    Tumour Stream Prostate
    Cancer Stage Metastatic or Widespread
    Anticipated Start Date
    Anticipated End Date

    Trial Summary

    A randomised phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castrate-resistant prostate cancer treated with enzalutamide (ANZUP 1901)

    Lay Summary

    A randomised phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castrate-resistant prostate cancer treated with enzalutamide (ANZUP 1901)

    Sponsor / Cooperative group

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Royal Adelaide Hospital Anne Milton anne.milton@sa.gov.au 08 7074 2342 Professor Hsiang Tan Not Yet Recruiting